Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson's disease trial.
Saved in:
| Title: | Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson's disease trial. |
|---|---|
| Authors: | Hutchison RM; Biogen, 300 Binney Street, Cambridge, MA, 02142, USA. matthew.hutchison@biogen.com., Evans KC; Biogen, 300 Binney Street, Cambridge, MA, 02142, USA., Fox T; Biogen, Maidenhead, UK., Yang M; Biogen, 300 Binney Street, Cambridge, MA, 02142, USA., Barakos J; Bioclinica, Princeton, NJ, USA., Bedell BJ; Biospective Inc., Montreal, QC, Canada., Cedarbaum JM; Coeruleus Clinical Sciences LLC, Woodbridge, CT, USA., Brys M; Eli Lilly and Company, Indianapolis, IN, USA., Siderowf A; University of Pennsylvania, Philadelphia, PA, USA., Lang AE; Morton and Gloria Shulman Movement Disorders Clinic, Toronto, ON, Canada.; Edmond J. Safra Program in Parkinson's Disease, Toronto, ON, Canada. |
| Source: | BMC neurology [BMC Neurol] 2021 Nov 23; Vol. 21 (1), pp. 459. Date of Electronic Publication: 2021 Nov 23. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Multicenter Study |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 100968555 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2377 (Electronic) Linking ISSN: 14712377 NLM ISO Abbreviation: BMC Neurol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1471-2377 |
|---|---|
| DOI: | 10.1186/s12883-021-02470-8 |
